Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.95
NVAX's Cash to Debt is ranked lower than
81% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. NVAX: 0.95 )
Ranked among companies with meaningful Cash to Debt only.
NVAX' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 11.65 Max: No Debt
Current: 0.95
Equity to Asset 0.11
NVAX's Equity to Asset is ranked lower than
89% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NVAX: 0.11 )
Ranked among companies with meaningful Equity to Asset only.
NVAX' s Equity to Asset Range Over the Past 10 Years
Min: 0.11  Med: 0.77 Max: 0.98
Current: 0.11
0.11
0.98
F-Score: 2
Z-Score: -3.50
M-Score: -8.74
WACC vs ROIC
20.85%
-442.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -1859.75
NVAX's Operating margin (%) is ranked lower than
83% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. NVAX: -1859.75 )
Ranked among companies with meaningful Operating margin (%) only.
NVAX' s Operating margin (%) Range Over the Past 10 Years
Min: -11502.46  Med: -824.36 Max: -134.38
Current: -1859.75
-11502.46
-134.38
Net-margin (%) -1908.41
NVAX's Net-margin (%) is ranked lower than
84% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NVAX: -1908.41 )
Ranked among companies with meaningful Net-margin (%) only.
NVAX' s Net-margin (%) Range Over the Past 10 Years
Min: -12414.15  Med: -880.1 Max: -129.13
Current: -1908.41
-12414.15
-129.13
ROE (%) -150.08
NVAX's ROE (%) is ranked lower than
88% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. NVAX: -150.08 )
Ranked among companies with meaningful ROE (%) only.
NVAX' s ROE (%) Range Over the Past 10 Years
Min: -150.08  Med: -43.4 Max: -32.12
Current: -150.08
-150.08
-32.12
ROA (%) -63.70
NVAX's ROA (%) is ranked lower than
75% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. NVAX: -63.70 )
Ranked among companies with meaningful ROA (%) only.
NVAX' s ROA (%) Range Over the Past 10 Years
Min: -63.7  Med: -33.19 Max: -22.37
Current: -63.7
-63.7
-22.37
ROC (Joel Greenblatt) (%) -816.16
NVAX's ROC (Joel Greenblatt) (%) is ranked lower than
59% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. NVAX: -816.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVAX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -816.16  Med: -427.33 Max: -182.47
Current: -816.16
-816.16
-182.47
Revenue Growth (3Y)(%) -6.30
NVAX's Revenue Growth (3Y)(%) is ranked lower than
63% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NVAX: -6.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVAX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -57.7  Med: 1.8 Max: 247.6
Current: -6.3
-57.7
247.6
EBITDA Growth (3Y)(%) 41.30
NVAX's EBITDA Growth (3Y)(%) is ranked higher than
88% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. NVAX: 41.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVAX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -58.7  Med: -6.2 Max: 102.6
Current: 41.3
-58.7
102.6
EPS Growth (3Y)(%) 39.70
NVAX's EPS Growth (3Y)(%) is ranked higher than
87% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. NVAX: 39.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVAX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -45.5  Med: -3.3 Max: 52.3
Current: 39.7
-45.5
52.3
» NVAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

NVAX Guru Trades in Q4 2015

Steven Cohen 384,300 sh (New)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q1 2016

NVAX Guru Trades in Q1 2016

George Soros 30,300 sh (New)
Steven Cohen Sold Out
» More
Q2 2016

NVAX Guru Trades in Q2 2016

Steven Cohen 180,000 sh (unchged)
George Soros Sold Out
» More
Q3 2016

NVAX Guru Trades in Q3 2016

Paul Tudor Jones 115,000 sh (New)
Chuck Royce 900,000 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with NVAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:OMED, NAS:GERN, NAS:LJPC, NAS:BSTC, NAS:ADAP, NAS:SVA, NAS:SPPI, NAS:EDGE, NAS:AKBA, NAS:SRNE, NAS:CRBP, NAS:CEMP, NAS:MESO, NAS:IMMU, NAS:FOMX, NAS:VYGR, AMEX:BTX, NAS:NLNK, NAS:SYRS, NAS:NDRM » details
Traded in other countries:NVV.Germany,
Novavax Inc is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

Novavax Inc was incorporated in 1987 under the laws of the State of Delaware. The Company is a clinical-stage Biopharmaceutical company focused on creating differentiated, value- upon current preventive options for a range of infectious diseases. The Company manages its business as one operating segment: developing recombinant vaccines. The Company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles ('VLPs') and recombinant nanoparticle vaccines combined with a single-use bioprocessing production system. These vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins. Its influenza VLPs contain three of the structural virus proteins that are important for fighting influenza: hemagglutinin (HA) and neuraminidase (NA), both of which stimulate the body to produce antibodies that neutralize the influenza virus and prevent its spread through the cells in the respiratory tract, and matrix 1 (M1), which stimulates cytotoxic T lymphocytes to kill cells that may already be infected. The Company's product pipeline targets a variety of infectious diseases and its vaccine candidates are currently in or have completed clinical trials that target pandemic influenza (H5N1), seasonal influenza and respiratory syncytial virus ('RSV'). The Company's main competitors includes sanofi pasteur, Inc, MedImmune, LLC (a subsidiary of AstraZeneca PLC), GlaxoSmithKline plc, Novartis, Inc., and Merck & Co., Inc., Protein Sciences Corporation. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential federal, state or local regulations.

Ratios

vs
industry
vs
history
P/B 8.31
NVAX's P/B is ranked lower than
75% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. NVAX: 8.31 )
Ranked among companies with meaningful P/B only.
NVAX' s P/B Range Over the Past 10 Years
Min: 1.02  Med: 3.86 Max: 42.34
Current: 8.31
1.02
42.34
P/S 25.83
NVAX's P/S is ranked lower than
65% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. NVAX: 25.83 )
Ranked among companies with meaningful P/S only.
NVAX' s P/S Range Over the Past 10 Years
Min: 6.47  Med: 59.74 Max: 1903.33
Current: 25.83
6.47
1903.33
Current Ratio 4.68
NVAX's Current Ratio is ranked higher than
53% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. NVAX: 4.68 )
Ranked among companies with meaningful Current Ratio only.
NVAX' s Current Ratio Range Over the Past 10 Years
Min: 0.44  Med: 4.42 Max: 37
Current: 4.68
0.44
37
Quick Ratio 4.68
NVAX's Quick Ratio is ranked higher than
55% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. NVAX: 4.68 )
Ranked among companies with meaningful Quick Ratio only.
NVAX' s Quick Ratio Range Over the Past 10 Years
Min: 0.44  Med: 4.37 Max: 37
Current: 4.68
0.44
37
Days Sales Outstanding 13.65
NVAX's Days Sales Outstanding is ranked higher than
83% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. NVAX: 13.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 13.65  Med: 73.44 Max: 289.75
Current: 13.65
13.65
289.75

Buy Back

vs
industry
vs
history
Yield on cost (5-Year) 7.00
NVAX's Yield on cost (5-Year) is ranked higher than
88% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 1.66 vs. NVAX: 7.00 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVAX' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 7
3-Year Average Share Buyback Ratio -22.20
NVAX's 3-Year Average Share Buyback Ratio is ranked lower than
69% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. NVAX: -22.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -29.9  Med: -19.3 Max: -8.1
Current: -22.2
-29.9
-8.1

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.41
NVAX's Price/Median PS Value is ranked higher than
86% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. NVAX: 0.41 )
Ranked among companies with meaningful Price/Median PS Value only.
NVAX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.07  Med: 0.94 Max: 22
Current: 0.41
0.07
22
Earnings Yield (Greenblatt) (%) -68.13
NVAX's Earnings Yield (Greenblatt) (%) is ranked lower than
91% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. NVAX: -68.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVAX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -169.5  Med: 0 Max: 0
Current: -68.13
-169.5
0

More Statistics

Revenue (TTM) (Mil) $15.81
EPS (TTM) $ -1.12
Beta2.46
Short Percentage of Float28.37%
52-Week Range $1.16 - 8.95
Shares Outstanding (Mil)271.25

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 15 42
EPS ($) -1.06 -0.64 -0.71 -0.59
EPS w/o NRI ($) -1.06 -0.64 -0.71 -0.59
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NVAX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: United States Steel Corp, Tuesday Morning Corp, Novavax Inc. Feb 08 2015 
Novavax Inc. Reports Operating Results (10-Q) Nov 08 2010 
Novavax Inc. Reports Operating Results (10-Q) Aug 06 2010 
Novavax Inc. Reports Operating Results (10-Q) May 10 2010 
Novavax Inc. Reports Operating Results (10-Q) Nov 09 2009 
Novavax Inc. Reports Operating Results (10-Q) Aug 10 2009 
Novavax Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
ETFs with exposure to Novavax, Inc. : December 5, 2016 Dec 05 2016
5 Stocks Hedge Funds Are Betting Against Insiders Nov 30 2016
Novavax to Participate in the Citi 2016 Global Healthcare Conference Nov 30 2016
Novavax to Participate in the Citi 2016 Global Healthcare Conference Nov 30 2016
ETFs with exposure to Novavax, Inc. : November 23, 2016 Nov 23 2016
Novavax to Present at the 28th Annual Piper Jaffray Healthcare Conference Nov 22 2016
Novavax to Present at the 28th Annual Piper Jaffray Healthcare Conference Nov 22 2016
Novavax, Inc. :NVAX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016 Nov 22 2016
Edited Transcript of NVAX earnings conference call or presentation 9-Nov-16 9:30pm GMT Nov 18 2016
NOVAVAX INC Financials Nov 17 2016
NOVAVAX INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Nov 16 2016
NOVAVAX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 14 2016
How the Zika virus could be a major bright spot for Novavax Nov 11 2016
Novavax continues to pursue RSV vaccines despite failed trial Nov 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)